Physician profile
Charles Wayne Gates
NPI 1649263757
$101.23
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.54 · 2020: $51.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.13 | 2020 | |
| Glaxosmithkline, LLC. | $22.58 | 2019 | |
| Stryker Corporation | $20.56 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$66,181.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.